2023
Malignant Melanoma in Older Adults: Different Patient or Different Disease?
Sasson D, Smetona J, Parsaei Y, Papageorge M, Ariyan S, Olino K, Clune J. Malignant Melanoma in Older Adults: Different Patient or Different Disease? Cureus 2023, 15: e34742. PMID: 36909026, PMCID: PMC9998075, DOI: 10.7759/cureus.34742.Peer-Reviewed Original ResearchMelanoma-specific survivalRecurrence-free survivalOlder patientsT2 tumorsNodal positivityMetastatic progressionOlder adultsConclusion Older adultsLog-rank testingKaplan-Meier analysisT4 tumorsYounger patientsT1 tumorsBreslow thicknessClinical outcomesTumor characteristicsTumor thicknessSingle institutionClinical behaviorMalignant melanomaLower incidenceHigh incidencePatientsConsecutive sampleAge groups
2001
Surgical Considerations in the Management of Malignant Melanoma of the Ear
Narayan D, Ariyan S. Surgical Considerations in the Management of Malignant Melanoma of the Ear. Plastic & Reconstructive Surgery 2001, 107: 20-24. PMID: 11176596, DOI: 10.1097/00006534-200101000-00004.Peer-Reviewed Original ResearchConceptsMalignant melanomaLocal recurrenceYale-New Haven HospitalUnknown primary sitePrimary malignant melanomaPalpable nodesDisseminated diseaseRadical resectionConsecutive patientsLocal excisionRegional recurrenceWorse prognosisTransit melanomaConservative excisionSurgical considerationsSkin graftsDifficult lesionsFasciocutaneous flapPatientsPrimary siteMelanomaCosmetic importanceRecurrenceExternal earLesions
2000
Regional Lymph Node Dissections In Malignant Melanoma
Lawton G, Ariyan S. Regional Lymph Node Dissections In Malignant Melanoma. Clinics In Plastic Surgery 2000, 27: 431-440. PMID: 10941563, DOI: 10.1016/s0094-1298(20)32738-3.Peer-Reviewed Original ResearchConceptsElective lymph node dissectionLymph node dissectionNode dissectionNegative nodesTherapeutic lymph node dissectionRegional lymph node dissectionSentinel lymph node dissectionClinical stage ITime of resectionPositive nodesRegional lymphadenectomySentinel lymphProphylactic excisionCutaneous melanomaPrimary tumorMalignant melanomaPrimary melanomaRegional nodesSurvival advantageStage IPatientsMetastatic cellsMelanomaDissectionClear benefitThe Use Of Isolated Limb Perfusion To Manage Recurrent Malignant Melanoma
Ma D, Ariyan S. The Use Of Isolated Limb Perfusion To Manage Recurrent Malignant Melanoma. Clinics In Plastic Surgery 2000, 27: 441-450. PMID: 10941564, DOI: 10.1016/s0094-1298(20)32739-5.Peer-Reviewed Original ResearchConceptsRecurrent malignant melanomaMalignant melanomaLimb perfusionTumor necrosis factor alphaRecurrent metastatic diseaseIsolated limb perfusionNecrosis factor alphaList of drugsHyperthermic ILPRecurrent diseaseMetastatic diseaseTumor loadLimb functionClinical trialsSurgical techniqueFactor alphaWound hygieneChemotherapeutic agentsMelanomaPerfusionDiseaseExtremitiesTreatmentHyperthermicTrialsSurgical Management Of The Primary Melanoma
Narayan D, Ariyan S. Surgical Management Of The Primary Melanoma. Clinics In Plastic Surgery 2000, 27: 409-419. PMID: 10941561, DOI: 10.1016/s0094-1298(20)32736-x.Peer-Reviewed Original Research
1996
Reconstructive Surgery in Melanoma Patients
Ariyan S. Reconstructive Surgery in Melanoma Patients. Surgical Oncology Clinics Of North America 1996, 5: 785-808. PMID: 8899945, DOI: 10.1016/s1055-3207(18)30353-3.ChaptersConceptsSurgical excisionFull-thickness skin graftingWide surgical excisionCost of hospitalizationSplit-thickness skinDepth of invasionEarly ambulationLocal recurrenceSurgical treatmentMelanoma patientsWide excisionWide resectionTumor thicknessCosmetic resultsPrimary closureFear of difficultySkin graftingMalignant melanomaReconstructive surgeryAnatomic sitesPrimary siteFurther experienceLocal flapsMethod of reconstructionExcision
1982
Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
Ariyan S, Kirkwood J, Mitchell M, Nordlund J, Lerner A, Papac R. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery 1982, 92: 459-63. PMID: 7112396.Peer-Reviewed Original ResearchConceptsBacillus Calmette-GuerinSurgical adjuvant immunotherapyMER-BCGAdjuvant immunotherapyControl groupHigh-risk malignant melanomaDisease-free survivalHigh-risk melanomaIntraoperative infiltrationImmunotherapy groupIntradermal vaccinationIntralymphatic immunotherapyRegional lymphadenectomyConsecutive patientsSurgical excisionCalmette-GuerinMalignant melanomaPatientsImmunotherapyMethanol-extractable residueLymphadenectomyRecurrenceMelanomaExtremitiesSame interval